Xenon Pharmaceuticals Inc.

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

XENE$41.39+2.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Expressed in thousands of U.S. dollars except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Collaboration revenue (note 9)	$—	$—	$7,500	$—
Operating expenses:
Research and development	74,985	49,702	136,185	93,952
General and administrative	19,244	19,402	38,282	34,193
Total operating expenses	94,229	69,104	174,467	128,145
Loss from operations	(94,229)	(69,104)	(166,967)	(128,145)
Other income:
Interest income	7,199	10,837	15,282	22,192
Foreign exchange gain	1,698	10	1,733	177
Total other income	8,897	10,847	17,015	22,369
Loss before income taxes	(85,332)	(58,257)	(149,952)	(105,776)
Income tax recovery (expense)	626	333	199	(79)
Net loss	$(84,706)	$(57,924)	$(149,753)	$(105,855)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities (note 5)	949	(443)	1,725	(2,135)
Comprehensive loss	$(83,757)	$(58,367)	$(148,028)	$(107,990)
Net loss per common share (note 10):
Basic and diluted	$(1.07)	$(0.75)	$(1.90)	$(1.36)
Weighted-average common shares outstanding (note 10):
Basic and diluted	78,953,445	77,671,128	78,820,474	77,632,864

-4-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.